FDA clears non-contact laser energy device for abdominal fat reduction

Dr. Kilmer

Dominion Aesthetic Technologies announced in late June that the FDA cleared its eon FR laser energy body contouring device for fat reduction of the abdomen.

“What’s novel about this device is that it has a non-contact automated articulated arm that hovers over the treated area delivering the 1064 nm wavelength energy, while simultaneously cooling the skin with feedback control,” says Suzanne L. Kilmer, M.D., founder of the Laser and Skin Surgery Center of Northern California and clinical professor of dermatology at University of California, Davis. “The device hovers over the patient so nothing is touching the patient or applied to the patient. It automatically moves along the pre-templated area, delivering the heat and cooling while maintaining temperatures that are comfortable for the patient while triggering apoptosis.”

Dr. Kilmer, who was among the investigators for eon FR and is a member of Dominion's Scientific Advisory Committee, says that fat reduction outcomes with the device are comparable to that of other 1064 nm body contouring technologies, at 11% to 13%. Researchers verified their results with ultrasound, she says.

Most patients describe the treatment as comfortable and were satisfied with results, according to Dr. Kilmer.

“Eon does cover a large area at once -you can actually add in areas, sequentially. So, you can do a smaller correction of fat or an entire abdomen,” she says.

In essence, a provider programs the patient’s treatment into the device and the eon FR does the rest.
Eon FR treatment takes about 15 minutes to perform, there is no downtime post-treatment and fat reduction takes from six to 12 weeks, according to the company.

POLL: How many nonsurgical fat reduction devices do you have in your office? 

As with any noninvasive fat reduction device, it’s important to set realistic patient expectations, according to Dr. Kilmer.

“With body contouring, you can only get rid of so much fat at a given time. Patients’ expectations have to be explained. You could do larger patients, you just have to do multiple treatments,” Dr. Kilmer says.

Disclosures:

Dr. Kilmer has received research support from and has been a medical advisory board member with Cutera (stock options), Cytrellis (stock options), Alastin, Allergan, Dominion, Pulse Biosciences, Lumenis Lutronic, Merz, Sciton, Sienna Labs, Solta/Valeant (advisory board only) and Syneron/Candela. She has received research support in the past year from Galderma, BTL, R2 Derm and Revance. She has stock in Avava and HintMD.